Oxford, UK – 15 June 2010. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has been invited to present at the British In Vitro Diagnostics Association (BIVDA) Trilateral Workshop: “Role and significance of in vitro diagnostics in the healthcare systems of the future”. Hosted at the French Embassy in Berlin from June 16 - 17, the workshop will consist of a series of sessions and chaired discussions, presenting state-of-the-art research in in vitro diagnostics (IVD) applications. On June 17, Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Dr. Anson’s presentation will explore how knowledge of the human genome and proteome can be used to design DNA and protein microarrays to screen for markers of cancers and autoimmune diseases. Dr. Anson will also present the results from an internal study, demonstrating the ability to identify a set of biomarkers in serum samples that can distinguish between cancerous and non-cancerous prostate cells, with sensitivity and specificity levels above 90%. Such advances will lead to the generation of more accurate diagnostic tests with greater discriminatory power, offering improved patient outcomes.
For more information about OGT’s biomarker discovery technologies, visit www.ogt.co.uk.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine.
www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure(TM): For research use only This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
